Tests Qishenyiqi pills for heart remodeling after a heart attack
Tests Qishenyiqi pills against placebo in adults with chronic heart failure after a heart attack.
Plain-language title generated from the registry record
Registry title: Qishenyiqi for Ventricular Remodeling After Myocardial Infarction
Key facts
- Where
- Jinan, ChinaSee the 3 sites
- Phase
- Phase 4
Where in China
- Jinan Central Hospital Affiliated to Shandong First Medical UniversityJinan, ChinaNo longer taking part
- Panpan HaoJinan, ChinaNo longer taking part
- Qianfoshan Hospital, Shandong UniversityJinan, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Qilu Hospital of Shandong University
- Trial code
- NCT06699407
- Record updated
- 21 November 2024
- Original description
The effects of Qishenyiqi dripping pill on cardiac remodeling in patients with chronic stable heart failure have not been reported. This project aims to clarify the efficacy and safety of Qishenyiqi in patients with chronic heart failure after myocardial infarction. Patients with chronic stable heart failure after myocardial infarction were selected and randomly divided into two groups: the treatment group was treated with Qishenyiqi dripping pills; The control group was given placebo treatment. After 12 months of follow-up, the effects of Qishenyiqi on cardiac remodeling and function and cardiovascular adverse events were evaluated. The results are helpful to provide a new treatment strategy for chronic heart failure.Read full original descriptionShow less
Efficacy and Safety of Qishenyiqi Dripping Pills in Patients With Ventricular Remodeling and Chronic Heart Failure With Reduced Ejection Fraction After Myocardial Infarction
The effects of Qishenyiqi dripping pill on cardiac remodeling in patients with chronic stable heart failure have not been reported. This project aims to clarify the efficacy and safety of Qishenyiqi in patients with chronic heart failure after myocardial infarction. Patients with chronic stable heart failure after myocardial infarction were selected and randomly divided into two groups: the treatment group was treated with Qishenyiqi dripping pills; The control group was given placebo treatment. After 12 months of follow-up, the effects of Qishenyiqi on cardiac remodeling and function and cardiovascular adverse events were evaluated. The results are helpful to provide a new treatment strategy for chronic heart failure.
Inclusion: 1) The history of acute myocardial infarction exceeds 3 months; 2) Symptoms and signs of heart failure have been stable for more than one month; 3) 18 years old or more; 4) NYHA cardiac function classified as grade II~IV; 5) LVEF≤40%；; 6) NT-proBNP≥450pg/ml；; 7) All subjects or their guardians must sign the subject consent before entering the trial.
Exclusion: 5) Patients who participated in clinical research of other drugs within 3 months before being selected; 1) Patients with the following diseases: nonischemic cardiomyopathy; valvular heart disease; congenital heart disease; obstruction of left ventricular outflow tract; severe decompensated heart failure; active myocarditis or pericardial disease; end-stage liver and kidney diseases; malignant tumor; 2) Planned to undergo cardiac surgery within 12 months; 3) Mechanical complications of myocardial infarction; 4) Pregnant or nursing, or having the intention to give birth within one year; 6) Patients with poor sound transmission windows are examined by transthoracic ultrasound.